Cargando…

Intradiscal Injection of Autologous Platelet-Rich Plasma Releasate to Treat Discogenic Low Back Pain: A Preliminary Clinical Trial

STUDY DESIGN: Preliminary clinical trial. PURPOSE: To determine the safety and initial efficacy of intradiscal injection of autologous platelet-rich plasma (PRP) releasate in patients with discogenic low back pain. OVERVIEW OF LITERATURE: PRP, which is comprised of autologous growth factors and cyto...

Descripción completa

Detalles Bibliográficos
Autores principales: Akeda, Koji, Ohishi, Kohshi, Masuda, Koichi, Bae, Won C., Takegami, Norihiko, Yamada, Junichi, Nakamura, Tomoki, Sakakibara, Toshihiko, Kasai, Yuichi, Sudo, Akihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Spine Surgery 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5481592/
https://www.ncbi.nlm.nih.gov/pubmed/28670405
http://dx.doi.org/10.4184/asj.2017.11.3.380
_version_ 1783245416047837184
author Akeda, Koji
Ohishi, Kohshi
Masuda, Koichi
Bae, Won C.
Takegami, Norihiko
Yamada, Junichi
Nakamura, Tomoki
Sakakibara, Toshihiko
Kasai, Yuichi
Sudo, Akihiro
author_facet Akeda, Koji
Ohishi, Kohshi
Masuda, Koichi
Bae, Won C.
Takegami, Norihiko
Yamada, Junichi
Nakamura, Tomoki
Sakakibara, Toshihiko
Kasai, Yuichi
Sudo, Akihiro
author_sort Akeda, Koji
collection PubMed
description STUDY DESIGN: Preliminary clinical trial. PURPOSE: To determine the safety and initial efficacy of intradiscal injection of autologous platelet-rich plasma (PRP) releasate in patients with discogenic low back pain. OVERVIEW OF LITERATURE: PRP, which is comprised of autologous growth factors and cytokines, has been widely used in the clinical setting for tissue regeneration and repair. PRP has been shown in vitro and in vivo to potentially stimulate intervertebral disc matrix metabolism. METHODS: Inclusion criteria for this study included chronic low back pain without leg pain for more than 3 months; one or more lumbar discs (L3/L4 to L5/S1) with evidence of degeneration, as indicated via magnetic resonance imaging (MRI); and at least one symptomatic disc, confirmed using standardized provocative discography. PRP releasate, isolated from clotted PRP, was injected into the center of the nucleus pulposus. Outcome measures included the use of a visual analog scale (VAS) and the Roland-Morris Disability Questionnaire (RDQ), as well as X-ray and MRI (T2-quantification). RESULTS: Data were analyzed from 14 patients (8 men and 6 women; mean age, 33.8 years). The average follow-up period was 10 months. Following treatment, no patient experienced adverse events or significant narrowing of disc height. The mean pain scores before treatment (VAS, 7.5±1.3; RDQ, 12.6±4.1) were significantly decreased at one month, and this was generally sustained throughout the observation period (6 months after treatment: VAS, 3.2±2.4, RDQ; 3.6±4.5 and 12 months: VAS, 2.9±2.8; RDQ, 2.8±3.9; p<0.01, respectively). The mean T2 values did not significantly change after treatment. CONCLUSIONS: We demonstrated that intradiscal injection of autologous PRP releasate in patients with low back pain was safe, with no adverse events observed during follow-up. Future randomized controlled clinical studies should be performed to systematically evaluate the effects of this therapy.
format Online
Article
Text
id pubmed-5481592
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Korean Society of Spine Surgery
record_format MEDLINE/PubMed
spelling pubmed-54815922017-06-30 Intradiscal Injection of Autologous Platelet-Rich Plasma Releasate to Treat Discogenic Low Back Pain: A Preliminary Clinical Trial Akeda, Koji Ohishi, Kohshi Masuda, Koichi Bae, Won C. Takegami, Norihiko Yamada, Junichi Nakamura, Tomoki Sakakibara, Toshihiko Kasai, Yuichi Sudo, Akihiro Asian Spine J Clinical Study STUDY DESIGN: Preliminary clinical trial. PURPOSE: To determine the safety and initial efficacy of intradiscal injection of autologous platelet-rich plasma (PRP) releasate in patients with discogenic low back pain. OVERVIEW OF LITERATURE: PRP, which is comprised of autologous growth factors and cytokines, has been widely used in the clinical setting for tissue regeneration and repair. PRP has been shown in vitro and in vivo to potentially stimulate intervertebral disc matrix metabolism. METHODS: Inclusion criteria for this study included chronic low back pain without leg pain for more than 3 months; one or more lumbar discs (L3/L4 to L5/S1) with evidence of degeneration, as indicated via magnetic resonance imaging (MRI); and at least one symptomatic disc, confirmed using standardized provocative discography. PRP releasate, isolated from clotted PRP, was injected into the center of the nucleus pulposus. Outcome measures included the use of a visual analog scale (VAS) and the Roland-Morris Disability Questionnaire (RDQ), as well as X-ray and MRI (T2-quantification). RESULTS: Data were analyzed from 14 patients (8 men and 6 women; mean age, 33.8 years). The average follow-up period was 10 months. Following treatment, no patient experienced adverse events or significant narrowing of disc height. The mean pain scores before treatment (VAS, 7.5±1.3; RDQ, 12.6±4.1) were significantly decreased at one month, and this was generally sustained throughout the observation period (6 months after treatment: VAS, 3.2±2.4, RDQ; 3.6±4.5 and 12 months: VAS, 2.9±2.8; RDQ, 2.8±3.9; p<0.01, respectively). The mean T2 values did not significantly change after treatment. CONCLUSIONS: We demonstrated that intradiscal injection of autologous PRP releasate in patients with low back pain was safe, with no adverse events observed during follow-up. Future randomized controlled clinical studies should be performed to systematically evaluate the effects of this therapy. Korean Society of Spine Surgery 2017-06 2017-06-15 /pmc/articles/PMC5481592/ /pubmed/28670405 http://dx.doi.org/10.4184/asj.2017.11.3.380 Text en Copyright © 2017 by Korean Society of Spine Surgery http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Akeda, Koji
Ohishi, Kohshi
Masuda, Koichi
Bae, Won C.
Takegami, Norihiko
Yamada, Junichi
Nakamura, Tomoki
Sakakibara, Toshihiko
Kasai, Yuichi
Sudo, Akihiro
Intradiscal Injection of Autologous Platelet-Rich Plasma Releasate to Treat Discogenic Low Back Pain: A Preliminary Clinical Trial
title Intradiscal Injection of Autologous Platelet-Rich Plasma Releasate to Treat Discogenic Low Back Pain: A Preliminary Clinical Trial
title_full Intradiscal Injection of Autologous Platelet-Rich Plasma Releasate to Treat Discogenic Low Back Pain: A Preliminary Clinical Trial
title_fullStr Intradiscal Injection of Autologous Platelet-Rich Plasma Releasate to Treat Discogenic Low Back Pain: A Preliminary Clinical Trial
title_full_unstemmed Intradiscal Injection of Autologous Platelet-Rich Plasma Releasate to Treat Discogenic Low Back Pain: A Preliminary Clinical Trial
title_short Intradiscal Injection of Autologous Platelet-Rich Plasma Releasate to Treat Discogenic Low Back Pain: A Preliminary Clinical Trial
title_sort intradiscal injection of autologous platelet-rich plasma releasate to treat discogenic low back pain: a preliminary clinical trial
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5481592/
https://www.ncbi.nlm.nih.gov/pubmed/28670405
http://dx.doi.org/10.4184/asj.2017.11.3.380
work_keys_str_mv AT akedakoji intradiscalinjectionofautologousplateletrichplasmareleasatetotreatdiscogeniclowbackpainapreliminaryclinicaltrial
AT ohishikohshi intradiscalinjectionofautologousplateletrichplasmareleasatetotreatdiscogeniclowbackpainapreliminaryclinicaltrial
AT masudakoichi intradiscalinjectionofautologousplateletrichplasmareleasatetotreatdiscogeniclowbackpainapreliminaryclinicaltrial
AT baewonc intradiscalinjectionofautologousplateletrichplasmareleasatetotreatdiscogeniclowbackpainapreliminaryclinicaltrial
AT takegaminorihiko intradiscalinjectionofautologousplateletrichplasmareleasatetotreatdiscogeniclowbackpainapreliminaryclinicaltrial
AT yamadajunichi intradiscalinjectionofautologousplateletrichplasmareleasatetotreatdiscogeniclowbackpainapreliminaryclinicaltrial
AT nakamuratomoki intradiscalinjectionofautologousplateletrichplasmareleasatetotreatdiscogeniclowbackpainapreliminaryclinicaltrial
AT sakakibaratoshihiko intradiscalinjectionofautologousplateletrichplasmareleasatetotreatdiscogeniclowbackpainapreliminaryclinicaltrial
AT kasaiyuichi intradiscalinjectionofautologousplateletrichplasmareleasatetotreatdiscogeniclowbackpainapreliminaryclinicaltrial
AT sudoakihiro intradiscalinjectionofautologousplateletrichplasmareleasatetotreatdiscogeniclowbackpainapreliminaryclinicaltrial